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ABSTRACT
Acne is a very common non-infectious skin
condition that is frequently treated in
dermatological practices. Because acne is often
chronic and may persist for years, safe and
effective long-term maintenance therapy is
often required. Given the increasing frequency
of antibiotic-resistant bacteria and the gravity of
the consequences of this trend, it behooves
dermatologists to maximize use of
non-antimicrobial therapy when treating acne.
In this review of the literature we present data
regarding the efficacy and appropriate use of
non-antimicrobial treatments for acne. A
variety of topical and oral treatment options
exist that can be used in a step-wise manner
according to the patients’ severity and
therapeutic response. Non-antimicrobial
treatments can be highly efficacious at
controlling acne, especially when used as
maintenance therapy. While antibiotics have a
role in acne treatment, they should not be used
as monotherapy, and lengthy courses of
antibiotic use are discouraged.
Keywords: Azelaic acid; Acne; Antibiotics;
Isotretinoin; Light therapy; Retinoids;
Spironolactone; Subantimicrobial
INTRODUCTION
Antibiotic overuse and the development of
antibiotic-resistant bacteria, coupled with a
dearth of new antimicrobial agents, have
resulted in a serious domestic and global
threat [1]. The scale and magnitude of this
threat is severe. A recent statement issued from
the Centers for Disease Control reported that
roughly 23,000 deaths occur annually in the
USA alone as a direct result of
antibiotic-resistant bacteria [1]. The trend of
increasingly antibiotic-resistant bacteria is
ongoing; even last-resort antibiotics, such as
colistin, which are used to treat
multidrug-resistant infections, are becoming
ineffective. For example, E. coli harboring the
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MCR-1 plasmid, which confers resistance to
colistin, has recently been discovered for the
first time in a human in the USA [2].
Dermatologists are in a unique position to
respond to the rising threat of
antibiotic-resistant bacteria: dermatologists
make up just 1% of all physicians but are
responsible for 4.9% of antibiotic prescriptions
[3]. Dermatologists primarily prescribe
antibiotics for the treatment of acne, and this
prescribing practice may have contributed to
the rise of antibiotic resistance. Responsible
antibiotic stewardship is increasingly
becoming recognized as an important
principle to incorporate into dermatology
practices.
Acne is one of the most common skin
disorders treated by dermatologists, affecting
between 40–50 million Americans [4]. While
acne is highly prevalent in youth with around
85% of teenagers affected at some point in time,
its occurrence is not uncommon in adults [5, 6].
The pathogenesis of acne is a multifactorial
process that involves the pilosebaceous unit and
results in a combination of non-inflammatory
(open and closed comedones) and
inflammatory (papules, pustules, nodules, and
cysts) lesions. Several distinct processes
contribute to the development of acne,
including the colonization of the skin with
Propionibacterium acnes, heightened levels of
inflammation, increased sebum production
and abnormal keratinization. Inflammation is
especially important in the disease process, and
several syndromes that are characterized by
profound systemic inflammation and
concurrent severe acne have been described:
pyogenic arthritis, pyoderma gangrenosum,
acne (PAPA syndrome); pyoderma
gangrenosum, acne, suppurative hidradenitis
(PASH syndrome); pyogenic arthritis,
pyoderma gangrenosum, acne, suppurative
hidradenitis (PAPASH syndrome); synovitis,
acne, pustulosis palmoplantaris, hyperostosis,
osteitis (SAPHO syndrome).
Acne can be successfully treated using a
multipronged approach by targeting its
underlying key mechanisms. Although acne is
not caused by an overabundance of P. acnes,
antibiotics have long played a central role in
acne therapy and have often been used as
monotherapy. Systemic antibiotics used for
acne treatment include tetracyclines
(tetracycline, doxycycline and minocycline),
macrolides (erythromycin and less often
clindamycin) and occasionally sulfonamides
(trimethoprim–sulfamethoxazole). The
therapeutic effect of systemic antibiotics is
thought to be due primarily to their
anti-inflammatory properties, and this is
especially true for the tetracyclines. Topical
antibiotics include clindamycin and
erythromycin.
Antibiotic overuse in the treatment of acne
has led to changing resistance patterns in P.
acnes. While only 20% of P. acnes showed
antibiotic resistance in 1978, roughly 2/3 are
resistant today [7–9]. Both systemic and topical
antibiotics are capable of changing the
antibiotic-resistance patterns in bacteria.
Topical erythromycin has been shown to
produce overgrowth of antibiotic resistance
bacteria both locally and at distant sites
[10, 11]. Similar resistance trends are also
likely to result from topical clindamycin
monotherapy.
Collateral damage to normal skin flora also
occurs as a result of antibiotic use. The normal
skin biome serves as an innate defense, and
changes in the skin biome brought on by
antibiotics can increase the risk of
colonization by pathologic organisms [12]. For
example, long courses of tetracycline induce
gram-negative bacterial overgrowth in the
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nares, and this is associated with gram-negative
folliculitis [13, 14]. Antibiotics used in the
treatment of acne are also associated with the
overgrowth of Streptococcus pyogenes and
Staphylococcus aureus in the oral pharynx, and
these changes may be linked to clinical
pharyngitis [15–17]. Furthermore, increased
rates of antibiotic-resistant bacteria
colonization is seen in family members of
acne patients who are treated with antibiotics
[18].
Given the risk associated with antibiotic use,
careful consideration must be given to the use
of this class of medications when treating acne.
In this systematic review of the literature we
present the efficacy data from randomized
clinical trials investigating non-antimicrobial
treatments for acne, highlighting the
appropriate use of these treatments as




A comprehensive search of the
English-language literature was performed on
PubMed using the following search terms:
‘‘acne,’’ ‘‘treatment’’ and ‘‘randomized’’ as well
as ‘‘photodynamic therapy,’’ ‘‘blue light’’ and
‘‘zinc’’ or ‘‘peel’’. Bibliographies of select
publications were reviewed for eligible studies.
Data Sources
We included randomized clinical studies
published before April 2016 that evaluated
presently available first- and second-line
topical, oral and physical treatment modalities
for acne. Inclusion criteria required a numeric
report of either the change in total lesion count
(TLC) for topical and oral treatments or the
change in inflammatory lesion count (ILC) for
studies evaluating physical treatment
modalities. Only studies that provided the
number of patients in each treatment group
were included in our final review. Studies
examining investigational treatments or
therapies not currently available in the USA
were excluded. Similarly, studies that solely
examined antimicrobial dosing of antibiotics
or studies that did not meet the above criteria
were excluded from this review. This article is
based on previously conducted studies and does
not involve any new studies of human or
animal subjects performed by any of the
authors.
Data Extraction
Data collection included the number of patients
per treatment group, details of treatment
regimens, severity and location of acne,
change in TLC or ILC following treatment,
and tolerability of treatment.
RESULTS
A total of 192 studies were found, of which 57
met the inclusion and exclusion criteria. Study
size ranged from 10 to 3010 patients, and
treatment duration ranged from 6 weeks to
6 months. When applicable, efficacy results
from trials examining matching treatment
regiments were reviewed together using a
weighted average. The majority of acne
treatment studies included either patients with
mild to moderate acne or those with moderate
to severe acne. Mild to moderate acne is
characterized by a predominance of open and
closed comedones, some papules and pustules,
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and few to no cysts or nodules. Patients with
predominantly inflammatory lesions, several
nodules or cystic lesions or patients who have
scarring acne are considered to have moderate
or severe acne. The results below are grouped
either based on the trend of acne severity
included in the associated studies or based on
select adjuvant treatment modalities such as
hormonal or physical treatment therapies.
Mild to Moderate Acne Treatment
First-line treatment options for mild to
moderate acne include a variety of topical
monotherapies and combination products:
retinoids, benzoyl peroxide (BPO),
clindamycin, clindamycin combined with BPO
and adapalene combined with BPO (Table 1).
Because clindamycin monotherapy is
discouraged, its efficacy will be reviewed here
primarily because it is used in combination
treatment regimens or combination products.
Alternative topical treatments include salicylic
acid, azelaic acid and dapsone. Low-dose
isotretinoin and oral zinc represent alternative
systemic treatment options.
Studies examining first-line treatment
options for mild to moderate acne reported a
range of efficacies, as measured by TLC
reductions, with the most impressive
outcomes often seen in combination therapies
treatment arms (Fig. 1) [19]. Clindamycin 1%
plus BPO 3% gel was the most efficacious
combination treatment (68.9% decrease in
TLC at 12 weeks) [20, 21]. Similarly, adapalene
0.1% and BPO 2.5% combination gel was highly
efficacious (65.4% TLC reduction at 12 weeks)
[22].
Topical retinoids are a mainstay of acne
treatment and have been in use since they
were first approved by the FDA in 1971.
Although thousands of retinoids have been
synthesized or described, only three are
approved for acne treatment in the USA:
tretinoin, adapalene and tazarotene. The first
retinoid to become available was a highly
concentrated tretinoin solution whose use was
limited by excessive skin irritation. With the
development of new vehicles, such as creams
and gels, the tolerability of tretinoin improved.
In an effort to further reduce
treatment-associated skin irritation, tretinoin
can now also be delivered as a large polymer
gel or cream or as a microsphere gel. Adapalene
and tazarotene are third-generation retinoids,
and each has distinct properties. Adapalene,
which is available as a gel, lotion, cream or
pledgets, has the unique property of being
stable in the presence of light and BPO.
Tazarotene, which is available as a cream,
foam or gel, is also approved for treating
psoriasis.
We reviewed efficacy data for the three
retinoids currently used in the USA, and all
were effective at decreasing the TLC when used
as monotherapy (Fig. 1) [22–37]. Webster et al.
reported a 71% TLC reduction with tretinoin
0.1% cream, which was the highest average TLC
reduction reported for all of the retinoids [36].
TLC reductions were similar among tretinoin
0.05% gel, tretinoin 0.025% gel and cream,
tretinoin 0.01% gel, tazarotene 1% foam, cream
and gel, tazarotene 0.05% gel as well as
adapalene 0.03% gel and adapalene 0.1%
lotion and gel. Lower TLC reductions were
seen with tretinoin 0.04% microsphere gel and
adapalene 0.1% cream. Efficacies varied with
the vehicle: adapalene 0.1% lotion and 0.1% gel
were similarly efficacious (53.7% and 53.6%
TLC reduction, respectively), and both were
more efficacious than adapalene 0.1% cream
(32.9% decrease in TLC). Similarly, tretinoin
0.025% gel was more efficacious than 0.025%
cream (54.7% and 52.5% TLC reduction).
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Topical retinoids were overall well tolerated
with the most commonly reported adverse
reactions being local skin irritation, erythema
and dryness. Retinoids will be discussed further
in the ‘‘Discussion.’’
BPO is an antimicrobial topical medication
that is a common component of acne treatment
regimens. There is no known bacterial
resistance to BPO, and it is available over the
counter as a cream, lotion, gel or wash at
concentrations ranging from 2.5% to 10%.
When evaluated as monotherapy, BPO was
moderately efficacious in decreasing acne
lesions [21, 22, 29]. Higher concentrations of
BPO were noted to result in larger TLC
reductions (61.8% vs. 50.3% for 3% gel and
2.5% gel, respectively) [21, 22, 29]. BPO was also
well tolerated with common side effects
including erythema and skin irritation.
Although topical clindamycin is not
recommended as monotherapy because of the
risk of antibiotic resistance, its efficacy as a
single agent has been evaluated in clinical trials
[20, 21, 30, 38–40]. Both clindamycin 1%
nanoemulsion gel and conventional
clindamycin gel were highly efficacious at
decreasing TLC (69.3% vs. 51.9%,
respectively), while clindamycin lotion only
produced a modest improvement (28.6%)
[39–41]. Clindamycin’s efficacy was enhanced
Table 1 Mechanism of action of topical products for the treatment of acne vulgaris
Dosage form/strength Primary mechanism of action Comedonal Inﬂammatory
Monotherapy
Adapalene Cream, gel or lotion: 0.1%
Gel: 0.3%
Anti-inﬂammatory, keratolytic X X
Tazarotene Cream or gel: 0.05%, 0.1%
Foam: 0.1%
Anti-inﬂammatory, keratolytic X X
Tretinoin Cream: 0.02%, 0.025%, 0.0375%, 0.05%,
0.075%, 0.1%
Gel: 0.01%, 0.025%, 0.04%, 0.05%, 0.1%
Microsphere gel: 0.04%, 0.08%, 0.1%
Anti-inﬂammatory, keratolytic X X
Benzoyl peroxide Gel, cream, lotion, pads or wash: 2.5–10% Antimicrobial X X
Azelaic acid Cream: 20%




Primary mechanism of action Comedonal Inﬂammatory
Combination treatment
Clindamycin/benzoyl peroxide Antimicrobial X X
Clindamycin/tretinoin Antimicrobial, anti-inﬂammatory, keratolytic X X
Clindamycin/adapalene Antimicrobial, anti-inﬂammatory, keratolytic X X
Clindamycin/salicylic acid Antimicrobial, anti-inﬂammatory, desquamation X X
Dapsone/adapalene Antimicrobial, anti-inﬂammatory, keratolytic X X
Dapsone/benzoyl peroxide Antimicrobial, anti-inﬂammatory X X
Erythromycin/zinc acetate Antimicrobial X
Erythromycin/benzoyl peroxide Antimicrobial X X
Erythromycin/tretinoin Antimicrobial, anti-inﬂammatory, keratolytic X X
Adapalene/benzoyl peroxide Antimicrobial, anti-inﬂammatory, keratolytic X X
Zinc pyrrolidone/seaweed-derived oligosaccharide Antimicrobial, anti-inﬂammatory X X




















































Fig. 1 Comparison of efﬁcacy of ﬁrst-line mild to mod-
erate acne treatments in reducing total acne lesion count.
BPO benzoyl peroxide. Clindamycin 1% ? BPO 3% gel:
Schaller et al. [20], Eichenﬁeld et al. [21]; clindamycin
1% ? BPO 5% gel BID: Langner et al. [30], Jackson et al.
[38]; clindamycin 1% ? tretinoin 0.025% lotion: Jackson
et al. [38], NilFroushzadeh et al. [39]; clindamycin
1% ? BPO 5% gel: Langner et al. [30]; clindamycin 1%
lotion ? adapalene 0.1% gel: Wolf et al. [40]. BPO 3% gel:
Eichenﬁeld et al. [28]; BPO 2.5% gel: Gollnick et al. [22],
Babaeinejad and Fouladi [29]. Tretinoin 0.1% cream:
Webster et al. [36]; tretinoin 0.025% gel: Cunliffe et al.
[35], Webster [36]; tretinoin 0.025% cream: Webster [36];
tretinoin 0.1% gel: Webster et al. [36]; tretinoin 0.05% gel:
Webster et al. [31], Tirado-Sa´nchez and Ponce-Olivera
[33]; tretinoin 0.04% microsphere gel: Berger et al. [32];
adapalene 0.1% ? BPO 2.5% combo gel: Gollnick et al.
[22]; adapalene 0.3% gel: Thiboutot et al. [23], Pariser
et al. [24], Tanghetti et al. [25], Tirado-Sa´nchez and
Ponce-Olivera [33]; adapalene 0.1% lotion: Eichenﬁeld
et al. [28]; adapalene 0.1% gel: Gollnick et al. [22],
Thiboutot et al. [23], Pariser et al. [24], Babaeinejad and
Fouladi [29], Langner et al. [30], Tirado-Sa´nchez and
Ponce-Olivera [33], Cunliffe et al. [35]; adapalene 0.1%
cream: Shalita et al. [26], Lucky et al. [34]; tazarotene 1%
cream: Tanghetti et al. [25], Shalita et al. [26]; tazarotene
1% foam: Feldman et al. [27]; tazarotene 0.1% gel: Shalita
et al. [37]; tazarotene 0.05% gel: Shalita et al. [37]. Asterisk
Treatment length varied from 12 weeks to 16 weeks.
Double dagger symbol Treatment length varied from 8 to
12 weeks. Dagger symbol Treatment length varied from
12 weeks to 90 days
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with the addition of salicylic acid: clindamycin
1% combined with 2% salicylic acid lotion
resulted in a TLC reduction of 77.9% [39].
Topical clindamycin was very well tolerated,
with side effects including mild burning,
stinging and scaling.
Azelaic acid is a non-antibiotic topical acne
treatment that is available as a 20% cream and a
15% gel or foam, and it is often used as an
adjuvant acne treatment. Azelaic acid has
comedolytic, antimicrobial and
anti-inflammatory properties. Twice daily
application of azelaic acid 20% cream was
found to be moderately effective at treating
mild to moderate acne with a 53.9% decrease in
TLC reported at 12 weeks [20]. Azelaic acid 15%
and 20% formulations will be discussed further
in the ‘‘Discussion.’’
Second-line therapies showed modest to
moderate improvement in TLC, with
combination treatments resulting in the
highest efficacies. Dapsone 5% gel alone
resulted in a modest TLC reduction (39.0% at
week 12), and this was enhanced with the
addition of adapalene 0.1% gel (51.0% at week
12) [42, 43]. Topical dapsone was very well
tolerated with common side effects including
mild pruritus and burning at the application
site, especially when combined with adapalene.
Erythromycin 4% with zinc acetate 1.2% has
been reported to produce moderate decreases in
TLC (64.5% in 12 weeks) [44]. A
seaweed-derived oligosaccharide complexed to
0.1% zinc pyrrolidone cream was also
moderately effective (61.2% decrease in TLC in
8 weeks) [45].
Low-dose isotretinoin has been evaluated as
a second-line systemic treatment for mild to
moderate acne. Isotretinoin used at low and
intermittent dosing (0.5 mg/kg daily for 1 out of
every 4 weeks for 24 weeks) was shown to be
highly efficacious (80.5% TLC reduction at week
24) [46]. This dosing regimen, however, is
uncommonly used because of the prescribing
restrictions that have resulted from the
iPLEDGE system.
Oral zinc sulfate has also been evaluated as a
second-line systemic treatment option for mild
to moderate acne; 220 mg of zinc sulfate dosed
three times daily produced a moderate TLC
reduction (45.5% at 12 weeks) [47]. This
treatment, however, was very poorly tolerated
with 40% of subjects reporting nausea or
vomiting.
Moderate to Severe Acne Treatment
Historically, long courses of antibiotics have
been used as first-line therapy for patients with
moderate to severe acne. Given the trend of
increasing antibiotic resistance, antibiotic
treatment as monotherapy is discouraged. In
lieu of long courses of antibiotics, other
first-line treatment options for moderate to
severe acne include oral isotretinoin or a
subantimicrobial oral antibiotic combined
with the topical therapies used for mild to
moderate acne.
Isotretinoin dosed at 0.5–1.0 mg/kg daily was
more efficacious than doxycycline 200 mg plus
adapalene 0.1%/benzoyl peroxide 2.5% gel at
reducing TLC (92.9% vs. 78.2%) [48]. Low-dose
isotretinoin (20 mg daily) combined with a 20%
salicylic acid peel applied every 2 weeks was
more efficacious than low-dose isotretinoin
alone (92.5% vs. 73.4% TLC reduction at week
16) [49].
The tolerability of isotretinoin will be
discussed further in the ‘‘Discussion.’’ Briefly,
isotretinoin dosed at 1 mg/kg has been
generally well tolerated, with patients
commonly reporting xerosis, cheilitis,
myalgias and gastrointestinal upset. Laboratory
abnormalities such as hypertriglyceridemia are
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also common. The most serious risk associated
with isotretinoin pertains to its teratogenic
effects.
Subantimicrobial doxycycline has been
evaluated in the treatment of moderate to
severe acne; 20 mg of doxycycline twice daily
was more efficacious than either 40 mg
modified release or 100 mg doxycycline once
daily (52.3%, 41.7% and 35.9% TLC reduction,
respectively) [50, 51]. The subantimicrobial
properties of doxycycline 40 mg
modified-release capsules were demonstrated
in a recent pharmacokinetics study: subjects
treated with doxycycline 40 mg failed to
achieve a mean steady-state doxycycline
plasma concentration that surpassed the
antimicrobial threshold, while those treated
with doxycycline 50 mg daily had steady-state
plasma concentrations that exceeded this
threshold [52]. Low-dose antibiotics will be
discussed further in the Discussion
section. Doxycycline was well tolerated with a
minority of patients reporting headache and
nausea.
Hormonal Therapies
Unique therapeutic options are available when
treating women with acne. Hormonal therapies,
such as combined oral contraceptive pills
(COCs) as well as spironolactone, are known
to improve female acne even in the absence of
concurrent hirsutism. Four COCs have been
approved by the FDA for acne treatment, while
spironolactone is used off label for this purpose
in women.
COCs have been evaluated for efficacy in
treating women with persistent acne and have
been found to have mild to moderate efficacy;
20 lg ethinyl estradiol/100 lg levonorgestrel
resulted in a mild decrease in TLC (31.1%)
after treatment for six cycles of 28 days [53, 54];
20 lg ethinyl estradiol/3 mg drospirenone was
moderately effective in decreasing facial and
truncal TLC (46.3% and 57.3%, respectively)
[55, 56]. COCs were well tolerated, with low
incidence of adverse events. Reported side
effects include metrorrhagia, vomiting and
allergic reaction.
Spironolactone, which is an aldosterone
receptor antagonist approved for the treatment
of hypertension, is known to have potent
antiandrogen properties and is used in clinical
practice off label for adult female acne.
Although well-designed randomized controlled
trials are lacking, expert opinion supports the
use of this overall well-tolerated and safe
treatment in select women [19]. Possible side
effects include breast tenderness, irregular
menses and gastrointestinal upset. Because of
the risk of developing gynecomastia, men are
excluded from using this off-label treatment.
Physical Therapies
While not currently considered first-line therapy
for acne, physical therapies can be useful in
select patients with moderate to severe acne who
have primarily inflammatory acne lesions.
Physical therapies for the treatment of acne
include phototherapy, photodynamic therapy
(PDT) and chemical peels. Photo therapy
involves exposing affected skin to a specific
light source such as long pulsed dye laser
(LPDL), intense pulsed laser (IPL) or various
wavelengths of light. Often, a photosensitizer,
such as aminolevulinic acid (ALA) or
methyl-ALA (MAL), is applied to the skin and
left on the skin for a certain time prior to
treatment with light. The combination of a
photosensitizer with light therapy is called PDT.
Although there was significant inter-study
heterogeneity with respect to acne severity,
number and frequency of treatments, PDT
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occlusion time, and study design, efficacy
trends can be appreciated when comparing the
various treatment modalities. Treatment with
IPL, which uses wavelengths of 400–1200 nm,
was found to have some of the most impressive
ILC reductions for treating mild to severe acne
(up to 90% decrease), and this efficacy may be
increased when treatment is combined with a
suction device to flatten the skin during
treatment (up to 90% decrease) [57–65]. IPL
efficacy did not appear to be significantly
enhanced when combined with PDT
[62, 64–68]. IPL’s efficacy may be due in part
to its longer wavelengths, which have the
ability to produce selective photothermolysis
of sebaceous glands; sebum has an absorption
peak at 1210 nm [69]. LPDL, which uses a
wavelength of 595 nm, was more effective at
decreasing ILC in patients with mild to severe
acne when combined with PDT (67% vs. 100%)
[70, 71]. Treatment with red (620–660 nm) and
blue (400–500 nm) light are both moderately
effective at decreasing ILC (up to 66% and up to
77%, respectively), and these efficacies can be
enhanced when combined with PDT
[58, 64, 67, 72–82]. Red light PDT appears to
be more effective when the photosensitizer is
incubated under occlusion compared to no
occlusion (59.4% and 31.7% ILC reduction,
respectively) [80]. Blue-red (400–500 plus
620–660 nm) light therapy may be superior to
either blue or red light alone, with ILC
reductions of up to 90% reported [58, 83–85].
Side effects related to light therapy limit its
use. The incidence of adverse events, such as
pain and burning, is relatively high in patients
using PDT. Patients have also reported
significant cutaneous erythema lasting for
several days post treatment. Postinflammatory
pigmentation alteration can also be associated
with PDT treatment.
Treatment of acne with chemical peels
involves application of a keratolytic agent
such as salicylic acid or glycolic acid to
promote desquamation. Glycolic acid and
amino fruit acid peels used at increasing
concentration applied over 24 weeks at 2-week
intervals were moderately effective in
decreasing non-inflammatory TLC (62.7% and
62.4%, respectively, at 6 months) [86].
Lipohydroxy acid and salicylic acid peels
applied over 12 weeks at 2-week intervals were
also moderately effective in decreasing
non-inflammatory TLC (55.6% and 48.5%,
respectively, at 98 days) [87].
DISCUSSION
Acne is a chronic, multifactorial skin disease
that is very common and can lead to disfiguring
scars. Because the pilosebaceous unit is the
primary structure involved, acne most
frequently occurs in areas of high
pilosebaceous unit density such as the face,
neck, chest and back [88].
Acne pathogenesis is complex, and our
understanding of this disease process
continues to evolve. Comedogenesis is
thought to be triggered by a combination of
abnormal desquamation of lipid-laden
keratinocytes within the sebaceous follicle plus
sebaceous gland hyperactivity. Androgens,
which control sebum production, are known
to contribute to the disease process. Increased
production and cohesion of the corneocytes
narrow the pilosebaceous opening to the skin
and result in a bottleneck phenomenon,
thereby producing a microcomedone. As the
comedone develops and expands, there can be
disruption of the follicular epithelium with
extrusion of sebum and corneocytes into the
interstitium, thereby leading to an
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inflammatory response. P. acnes, which is a
ubiquitous commensal gram-positive rod, is
found in higher concentrations on
acne-affected skin. P. acnes is also known to
stimulate an inflammatory response and
facilitate comedone rupture. While P. acnes is
involved in the disease process, its density is not
correlated with acne severity and acne may
occur even without its presence. For example,
microcomedones are known to form in children
with early acne prior to P. acnes colonization
[89]. Furthermore, eradicating P. acnes may
improve acne but will not produce a ‘‘cure’’ of
the disease [90].
A plethora of non-antibiotic topical and
systemic acne treatment options are available
and include topical retinoids, BPO,
combination products, azelaic acid,
isotretinoin, subantimicrobial dosed
antibiotics, hormonal therapies and physical
modalities. These treatment options can be used
in a step-wise manner depending on the disease
severity, patient characteristics and patient’s
therapeutic response.
In the mild to moderate acne group,
combination topical treatment is often
effective for both induction and maintenance
therapy. A variety of different monotherapy or
combination treatment options exist that target
distinct key aspects of the acne disease process.
Topical retinoids, which are vitamin A
derivatives, are one of the mainstays of acne
treatment. This class of medication targets the
initial step of comedogenesis by normalizing
follicular keratinization, thereby preventing the
development of new comedones and hastening
the resolution of existing lesions. Topical
retinoids also have anti-inflammatory
properties and are not antimicrobial.
Monotherapy with a topical retinoid is an
excellent choice for patients with
predominantly comedonal acne [19].
A variety of topical retinoids are available in
differing strengths and vehicles: tretinoin
0.025–0.1% as a cream, gel or microsphere;
adapalene 0.1–0.3% cream or 0.1% lotion;
tazarotene 0.05–0.1% cream, gel or foam. As
each of these products targets different
combinations of retinoic acid receptors in the
skin, there are slight differences in terms of
efficacy and tolerability between these
medications (Fig. 1). Several head-to-head
studies have been conducted evaluating the
efficacy of topical retinoids; however because
different concentrations and vehicles were used
it is difficult to make meaningful comparisons
between these medications [23, 24, 31, 91, 92].
A range of efficacies have been reported for
topical retinoids with the majority of studies
reporting a TLC reduction of between 40–60%
(Fig. 1) [23, 24, 26–28, 31, 92]. As expected,
increasing strength was on average correlated
with increased efficacy for each of the three
retinoids. The vehicle was also found to play an
important role in determining efficacy; with few
exceptions, gels conferred a larger TLC
reduction when compared to creams. Two
notable exceptions to this trend were tretinoin
0.05% gel, which was found to be less
efficacious than tretinoin 0.025% cream, and
tretinoin 0.04% microsphere gel, which was less
effective than tretinoin 0.025% cream. Because
these comparisons are not from head-to-head
studies, the results must be interpreted with
caution. More head-to-head studies are needed
to further define the individual efficacies of
each of the topical retinoids in relation to each
other.
Topical retinoid use is limited by skin
irritation, erythema and peeling, all of which
can be mitigated with the use of a less potent
retinoid for initial therapy and by starting
treatment with alternate evening use.
Tolerability can also be enhanced by using
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tretinoin-impregnated microsphere gel, which
was specifically formulated to have decreased
depth of penetration [93]. Improved tolerability
is likely to increase patient compliance with
treatment. Tretinoin and adapalene are
pregnancy category C, while tazarotene is
category X and must be avoided in pregnant
patients.
Because retinoids improve the abnormal
keratinization seen in acne, they also enhance
the delivery and efficacy of other topical
treatments such as benzoyl peroxide and
topical antibiotics (Fig. 1). Topical retinoids are
thus an excellent choice for patients with mixed
or inflammatory acne as these products can be
used concurrently with other topical treatments
or can be used in one of the combination
products [19]. Combination therapy using a
topical retinoid can be highly efficacious, and
currently available combination products
containing retinoids include adapalene 0.1%/
BP 2.5% and tretinoin 0.025%/clindamycin
[22, 38, 94].
BPO is a topical bactericidal and mildly
comedolytic OTC product. Similar to topical
retinoids, BPO is a cornerstone of maintenance
therapy for mild to moderate acne and is
commonly used as part of a combination
treatment regimen. While few head-to-head
studies examining the efficacy of BPO
monotherapy have been done, a recent
meta-analysis found that 5% BPO plus salicylic
acid was similar in efficacy to BPO plus topical
clindamycin [95]. BPO alone or in combination
with topical erythromycin has been reported to
be as efficacious as oral minocycline 100 mg
once daily, thus making this a compelling
alternative treatment regimen to long courses
of systemic antibiotics [96].
BPO’s mechanism of action is through the
release of free oxygen radicals. No resistance in P.
acnes has been reported to date. A variety of
strengths and concentrations are available,
ranging from 2.5–10% in creams, foams, gels
and washes. Side effects result from skin
irritation and include erythema and dryness. In
addition, fabric bleaching can result when
clothing and linens come into contact with BPO.
Salicylic acid is also an over-the-counter
product that has mild comedolytic and
anti-inflammatory properties. Available in
concentrations of up to 2%, salicylic acid can
be delivered in an array of vehicles including
washes, creams, foams and gels. Clinical trials
evaluating the efficacy of salicylic acid are
lacking.
Macrolides are the most commonly used
topical antibiotics for treating acne, of which
topical clindamycin is the preferred agent
because of high levels of resistance to
erythromycin [11]. Clindamycin has both
anti-inflammatory and antimicrobial
properties. In order to prevent resistance in P.
acnes, topical antimicrobials are most
appropriately used either in conjunction with
other topical treatments or as part of a
combination product [19]. Clindamycin
combination products include clindamycin 1%
with either BPO 3.75% or 5% [20, 21, 30, 38].
Clindamycin is available as a 1% gel, lotion or
solution and is very well tolerated.
Dapsone is an alternative topical antibiotic
that treats acne primarily via its
anti-inflammatory properties. When used as a
monotherapy, dapsone is modestly efficacious
with TLC reductions reported around 40%;
however, the efficacy can be enhanced when
dapsone is used concurrently with either BPO or
tretinoin [42, 43]. Inflammatory lesions and
adult female acne respond best to dapsone,
which is available as a 5% gel [97, 98]. Topical
dapsone is well tolerated, and
glucose-6-phosphate dehydrogenase levels do
not need to be checked prior to use [19].
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Azelaic acid, which is a non-antibiotic, has
mild comedolytic and anti-inflammatory
properties and is bactericidal against a range of
gram-negative and -positive organisms
including P. acnes [99, 100]. The
anti-inflammatory properties of azelaic acid are
twofold: azelaic acid downregulates
inflammatory cytokines and scavenges reactive
oxygen species [101–104]. Because azelaic acid
also has skin-lightening properties, it is often
the preferred agent for treating patients with
post-inflammatory hyperpigmentation from
acne lesions. Azelaic acid is available as a 20%
cream and a 15% gel and foam, all of which are
well tolerated. Although the gel and foam
formulations have a lower concentration of
active ingredient, these vehicles provide
enhanced skin penetration and thus improved
efficacy when compared to the cream, and
patients may prefer these vehicles over the
cream [105–107]. The 15% azelaic acid
strength is FDA approved for inflammatory
rosacea but is commonly used off label for
acne treatment, especially in pregnant women
[108]. More studies are needed evaluating the
use of azelaic acid as a single agent or as part of a
combination regimen for the treatment of acne.
Two novel topical acne treatments are
currently in clinical trials: SB204 gel as well as
DRM01 gel. SB204, which is the first in its class
as a topical nitric oxide-releasing medication,
has both anti-inflammatory and antimicrobial
properties [109, 110]. Phase 2 studies show
SB204 to be a promising acne treatment that is
well tolerated and effective against
inflammatory and non-inflammatory lesions.
SB204 is currently in phase 3 trials. DRM01 is a
small molecule that targets acetyl coenzyme-A
carboxylase, which is an important enzyme in
the synthesis of sebum. DRM01 has
demonstrated good efficacy and safety results
in phase 2 studies, and it has been selected to
undergo further evaluation in an upcoming
phase 3 trials [111].
Topical treatment modalities alone are often
inadequate in patients with moderate to severe
acne; these patients will often require systemic
therapy for their acne. Antibiotics have long
played a principal role in acne treatment in this
group of patients. The efficacy of antibiotics in
treating acne may be due more to their
anti-inflammatory properties than their
antimicrobial effects [112, 113]. Although
topical and systemic antibiotics continue to
have an important and appropriate role in acne
pharmacotherapy, especially for moderate to
severe acne, their overuse is associated with
significant population-wide risks, and there are
numerous non-antimicrobial treatments
available. Because acne is a chronic disease
spanning from adolescence well into
adulthood, many patients are treated
continuously for years with oral and/or topical
antibiotics. Antibiotic consumption is also
increasing worldwide, which is a concerning
trend given the increasing prevalence of
antibiotic-resistant bacteria and the lack of
novel antibiotics [114]. There is mounting
pressure to use antibiotics more judiciously
and decrease unnecessary prescribing, with the
CDC now recommending the use and
expansion of antibiotic stewardship programs
that aim to change prescribing habits
[115–117].
Induction therapy for moderate to severe
acne with systemic antibiotics is currently
considered appropriate, however in order to
minimize the risk of promoting antibiotic
resistance these medications should not be
used as monotherapy, and their duration
should be limited to 3 months or less
[118–121]. Prior to starting antibiotics,
bacterial culture and sensitivity can be
obtained as this information can help direct
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treatment choice and length [122]. The risks of
antibiotic treatment, including dyschromia,
pseudotumor cerebri and allergic reactions,
should be discussed with patients and their
families as the public is often uninformed about
the risks of and alternatives to antibiotics. If
induction therapy is required again in the
future because of a flare in the disease,
re-treatment should be done using the same
antibiotic that was used initially if it was
effective in order to avoid exposing the patient
to numerous antibiotics and reduce the risk of
developing resistant bacteria [90].
In addition to systemic treatment with
antibiotics, alternative treatments exist such as
subantimicrobial dosing of doxycycline.
Systemic doxycycline, when dosed at 20 mg
twice daily or 40 mg daily, exerts a therapeutic
anti-inflammatory effect without the untoward
effect of producing antibiotic resistance
[50, 51]. Subantimicrobial dosing of
doxycycline has been shown to be superior at
decreasing TLC when compared to doxycycline
100 mg dosed once daily [50]. Further research
into the area of subantimicrobial dosing of
other antibiotics may prove fruitful and
deliver new systemic treatment options for
patients with moderate to severe acne.
Isotretinoin is also an important
non-antibiotic therapeutic option for patients
with moderate to severe acne. This group of
patients is often treated for excessive lengths of
time with systemic antibiotics prior to being
treated with isotretinoin [123]. Patients who are
unable to transition off of oral antibiotics after
3 months of induction treatment or patients
with active scarring acne should be considered
for isotretinoin [19, 123].
Isotretinoin, which is highly effective at
producing long-lasting remission in patients
with severe acne, works by shrinking
sebaceous glands [124]. A typical starting dose
is around 0.5 mg/kg/day, and this is increased,
as tolerated by the patient, to a goal dose of
1.0 mg/kg/day [125]. Because there is an inverse
relationship between a patient’s cumulative
dose and risk of relapse, it is recommended
that patients reach a cumulative dose of
120–150 mg/kg before cessation of therapy
[126]. Some authors have advocated for even
higher cumulative doses up to 220 mg/kg as this
appears to significantly decrease the risk of
relapse without increasing serious
treatment-related adverse events [127].
Isotretinoin is known to have numerous side
effects, the majority of which are temporary and
resolve with discontinuation of therapy.
Musculoskeletal aches, cheilitis,
hypertriglyceridemia and ophthalmic
symptoms are most common. While it has
been suggested that there is a relationship
between isotretinoin treatment and both
inflammatory bowel disease and depression,
the majority of studies have not found
evidence to support any causal association
[128–131]. The most serious established risk of
isotretinoin is that which is posed to the fetus.
Because of the highly teratogenic effects of
isotretinoin, all patients treated with
isotretinoin must participate in the iPLEDGE
system, and female patients of child-bearing
potential must use effective contraception.
The treatment of acne in women requires
important consideration, as women comprise
over 60% of clinic visits for acne and have a
higher incidence than men of late-onset acne
developing after age 25 [132, 133]. Moreover,
acne in women can be difficult to treat and can
become persistent, and women are four times
more likely to have severe acne than men [5].
Cosmetics or skin care products used by women
do not appear to be responsible for the
increased prevalence of acne in women, and
the microflora of the skin in women with late
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onset acne compared to adolescents with acne is
essentially the same, indicating that the
pathogenesis of acne is likely not related to
microflora differences [133, 134].
Androgens play a role in the development of
acne through stimulation of sebaceous glands.
The importance of androgens in the
pathogenesis of acne can be appreciated by the
fact that androgen-insensitive subjects neither
produce sebum nor develop acne and by the fact
that hyperandrogenic states such as polycystic
ovarian disease produce acne that is highly
responsive to anti-androgen agents [135, 136].
Conditions such as polycystic ovarian syndrome
can cause elevated androgen levels leading to
acne development, and such conditions should
be considered in women with late-onset acne
that is resistant to conventional treatments.
While most women with acne have normal
levels of serum androgens, there may still be a
hormonal acne trigger such as menstrual cycle-
associated flares. This phenomenon can be
explained by an increased androgen sensitivity
in these individuals [137].
COCs treat acne through their
anti-androgenic properties. COCs contain
estrogen and progestin, which cause an
increase in sex hormone-binding globulin,
which binds free androgens and also exerts a
negative feedback to decrease ovarian androgen
production. There are four currently FDA
approved COCs: ethinyl estradiol/norgestimate,
ethinyl estradiol/norethindrone acetate/ferrous
fumarate, ethinyl estradiol/drospirenone and
ethinyl estradiol/drospirenone/levomefolate.
Drospirenone is a unique progestin with
structural similarities to spironolactone. While
COCs have been shown to be superior at
reducing moderate acne compared to placebo,
no conclusive data exist to suggest that one COC
is superior over another [19, 138]. COCs can be
used to treat acne in women with or without
signs of hyperandrogenism, and COCs also
provide the added benefits of contraception
and regulation of heavy periods. Side effects
include increased risk for thromboembolic
events, myocardial infarction and a
controversial association with cervical and
breast cancer. There is no conclusive evidence
supporting weight gain in association with
COCs.
Spironolactone is an aldosterone receptor
antagonist that also has anti-androgenic
properties by blocking cutaneous androgen
receptors [19]. Spironolactone may also inhibit
androgen synthesis and decrease steroid
hormone-binding globulin [139]. While
randomized controlled trials evaluating
spironolactone in treating acne are lacking, this
medication can be used in select women as
monotherapy or can be combined with other
drugs. Men should not be treated for acne with
spironolactone because of the risk of
gynecomastia. This medication should
specifically be considered in women with
hirsutism, those with hormonally triggered
acne, women with severe acne recalcitrant to
standard therapies or women with late-onset
acne vulgaris. Spironolactone dosing for acne
treatment ranges from 25–200mg daily and is
usually well tolerated; side effects are usually
dose dependent. Usually the 25–50 mg daily
dose does not cause significant side effects;
higher doses can cause diuresis, menstrual
irregularities, and breast tenderness and
enlargement [140]. A recent paper reported that
there is no need for routine potassium
monitoring for hyperkalemia in healthy young
women taking spironolactone for acne [141].
Spironolactone has a black box warning, as it has
been implicated as being a possible teratogen
and thus should be avoided in pregnancy.
Topical anti-androgens, though not available
for use in clinical practice, are an exciting area
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of clinical research and potential future
treatment option for men. These
investigational products have been the subject
of intense research given that they have
promising efficacy results for treating acne and
they minimize systemic side effects of
anti-androgens. Cortexolone 17a-propionate
1% cream applied daily for 8 weeks decreased
TLC in men by 65.7%, with no serious adverse
effects [142]. Topical 5% spironolactone gel
applied for 6 weeks was also shown to be
effective in reducing TLC by 70.9% in mild to
moderate acne [143].
Select patients with a predominance of
inflammatory lesions may benefit from
treatment with physical modalities. Physical
therapies include chemical peels, light therapy
with or without accompanying photosensitizer,
comedo removal and intralesional steroids.
Comedo removal is the process of extracting
acne lesions through application of pressure
close to the acne pore or through incision and
expression of contents. Such a practice can offer
immediate relief for the patient, but it can result
in scarring and incomplete evacuation of lesion
contents. This practice is also not supported by
extensive evidence in peer-reviewed papers
evaluating its efficacy; hence, it should only be
used when comedones persist after other
therapies are ineffective [19].
Chemical peels are an effective alternative
treatment option for patients with
non-inflammatory acne lesions. Active
ingredients in chemical peels, such as salicylic
acid and glycolic acid, work by decreasing the
connections between keratinocytes, thereby
leading to desquamation [144]. Salicylic acid
also decreases activity of the arachidonic acid
pathway, thereby decreasing perilesional
inflammation [145]. Evidence suggests that
chemical peels may improve comedonal acne.
However, multiple treatments are often
necessary and may not produce lasting
improvement; thus, there is little evidence to
support its use in routine first-line acne
treatment [19].
Light therapy is a moderately to highly
effective method for treating inflammatory
acne. Light therapy treats acne primarily
through activation of porphyrins, leading to
the destruction of P. acnes. The longer
wavelengths used in IPL may also destroy
sebaceous glands. Of the light therapies, IPL
appears to have the greatest therapeutic effect.
Both red and blue light are commonly used for
acne treatment, and both appear to be more
effective when combined with PDT. ALA, a
commonly used photosensitizer, is taken up by
sebaceous glands and produces reactive oxygen
species (ROS) when activated by red or blue
light [82]. These ROS then cause sebaceous
gland damage and destruction of P. acnes.
MAL, which is a commonly used
photosensitizer outside of the US, has also
been used in PDT for acne treatment and has
demonstrated significant efficacy in decreasing
ILC [146]. PDT shows great promise in treating
acne ranging from mild to severe, but the
optimal choice of photosensitizer and light
source are topics still under investigation [19].
Moreover, the side effects associated with PDT,
including moderate to severe pain during
treatment and post-treatment erythema, limit
its use, and more effective solutions to address
these side effects are necessary for this
treatment modality to become more widely
used.
Intralesional steroid injection, using
triamcinolone acetonide injected into the
center of the acne lesion, can be useful in
decreasing individual nodulocystic acne lesions,
especially when desiring rapid resolution.
However, steroid injections can cause local
skin atrophy and telangiectasias; thus, care
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should be taken to use this treatment modality
sparingly [147].
Microdermabrasion is a minimally invasive
procedure that involves varying degrees of
controlled abrasion of the skin to treat a
variety of conditions. Although
microdermabrasion is generally not used to
treat acne vulgaris, it is a commonly employed
technique for treating acne scars and can
produce mild to moderate improvement in
skin contour irregularities [148].
CONCLUSION
Overuse of antibiotics has resulted in
antibiotic-resistant bacteria, and this
development poses a major public health
concern for the future. Dermatologists play a
vital role in addressing this problem by
practicing proper stewardship in prescribing
antibiotics.
It is important to realize that while
antibiotics play a crucial role in the treatment
of acne, they should be used judiciously.
Systemic antibiotics, when used as induction
therapy for 3 months, are an appropriate
component of treatment for moderate to
severe acne patients. After induction therapy
patients should be transitioned off of systemic
antibiotics and onto a maintenance therapy
regimen. If, however, they have not cleared or if
they cannot successfully transition to
maintenance therapy, the possibility of
treatment failure should be considered, and
next line therapy with isotretinoin may be
required.
Non-antibiotic treatments have been shown
to improve acne significantly and should be
used in place of antibiotics when possible,
especially for maintenance treatment. Benzoyl
peroxide and topical retinoids should have a
central role in acne maintenance treatment.
Combination therapies, hormonal therapies,
and physical treatment modalities are also
effective in reducing acne lesions and should
be considered in select patients when
appropriate.
Further research is needed evaluating the
efficacy of non-antimicrobial treatments for
acne with a specific focus on optimizing
combination products or treatments regimens
and on optimizing the use of physical
modalities for acne treatment. Research
evaluating the efficacy of azelaic acid has
primarily focused on the treatment of rosacea;
however, this medication has significant
therapeutic potential for acne treatment,
especially if used in combination with other
topical non-antimicrobial treatments. Research
evaluating sub-antimicrobial dosing of
antibiotics other than doxycycline may reveal
new therapeutic options for acne treatment.
Finally, novel and promising non-antibiotic
treatments are currently in development for
acne treatment, and we anticipate that these
will ultimately enhance the non-antibiotic
treatment options available for acne patients.
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